Abstract A034: Baseline characteristics of participants enrolled in a randomized controlled trial of a diet and physical activity intervention among Hispanic/Latina breast cancer survivors (in progress)
Authors: Ulanday Kathleene T. , Santiago-Torres Margarita , Shi Zaixing , Paul Rachel , Marin-Chollom Amanda , Castellano Marisol , Fuentes Yanette , Contento Isobel , Koch Pam , Gray Heewon L. , Gaffney Ann O. , Hershman Dawn , Greenlee Heather 
Published: August 2020

Background: Cancer survivors are recommended to consume a diet high in fruits and vegetables (F/V), low in energy dense foods, and engage in 150 minutes of moderate-to-vigorous physical activity (MVPA). Hispanic/Latina breast cancer (BC) survivors have higher rates of obesity and lower rates of physical activity compared to non-Hispanic white women. The Mi Vida Saludable (My Healthy Life) trial is testing the effectiveness of a culturally based behavioral intervention on improving and maintaining diet and physical activity changes among Hispanic/Latina BC survivors (R01CA186080, PI: H Greenlee). The primary outcomes are changes, from baseline to 12 months, in daily servings of F/V, total energy density, and physical activity.

Methods: Mi Vida Saludable is a 2 × 2 factorial randomized controlled trial conducted in Hispanic/Latina BC survivors living in New York City. The eligibility criteria include: self-identified as Hispanic/Latina female; aged 21 years; diagnosed with stage 0-III BC with no detectable disease; &gt;3 months post-treatment (current use of hormonal therapy allowed); have access to text messaging and the Internet; and available for Saturday intervention classes. Additional eligibility criteria include intake of &lt;5 servings of F/V per day (assessed using NIH's Quick Food Scan Questionnaire) and/or &lt;150 minutes of MVPA per week (assessed via a modified International Physical Activity Questionnaire Short Form). Baseline data collection includes self-reported demographic, medical history, anthropometric measures, technology use, diet, and physical activity. Participants (target enrollment n=200) are randomized to four arms: A) in-person education plus e-communication, B) e-communication alone, C) in-person education alone, or D) control. Randomization is stratified on preferred language (English vs. Spanish) and current use of hormonal therapy. All participants receive a Fitbit, 30-minute health coaching session, and printed materials. Here, we report the screening and baseline characteristics of participants enrolled to date.

Results: As of July 2018, a total of 128 participants have been enrolled and randomized into the study. Baseline characteristics include: mean age of 56 years (SD 9), 56% with annual household income $15,000, 54% with some college education or higher, 44% overweight (BMI 25-&lt;30 kg/m2), 41% obese (BMI 30 kg/m2), mean time since diagnosis 5 years (SD 4), average 2 servings/day of F/V (SD 1), and mean 51 minutes/week of MVPA (SD 92), 59% comfortable using email, and 80% comfortable using text messaging.

Conclusion: To date, the majority of participants enrolled are overweight/obese and on average do not meet the recommendations for cancer survivors on daily F/V intake and MVPA. Over half of participants enrolled have some college education or more, and more women are comfortable using text messaging compared to email. Trial enrollment will be completed in fall 2019 with a target goal of 200 participants.

Citation Format: Kathleene T. Ulanday, Margarita Santiago-Torres, Zaixing Shi, Rachel Paul, Amanda Marin-Chollom, Marisol Castellano, Yanette Fuentes, Isobel Contento, Pam Koch, Heewon L. Gray, Ann O. Gaffney, Dawn Hershman, Heather Greenlee. Baseline characteristics of participants enrolled in a randomized controlled trial of a diet and physical activity intervention among Hispanic/Latina breast cancer survivors (in progress) [abstract]. In: Proceedings of the Eleventh AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2018 Nov 2-5; New Orleans, LA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl):Abstract nr A034.